Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Symbol: 1349.HK

HKSE

2.61

HKD

Market price today

  • 0.0000

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 8.94B

    MRK Cap

  • 0.03%

    DIV Yield

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349-HK) Stock Price & Analysis

Shares Outstanding

3424.51M

Gross Profit Margin

0.93%

Operating Profit Margin

0.23%

Net Profit Margin

0.21%

Return on Assets

0.06%

Return on Equity

0.09%

Return on Capital Employed

0.09%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO:Mr. Da Jun Zhao
Full-time employees:910
City:Shanghai
Address:Zhangjiang Hi-Tech Park
IPO:2002-08-13
CIK:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

General Outlook

In simple terms, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. has 3424.51 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.927% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.227%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.207%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.064% return, is a testament to Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s adeptness in optimizing resource deployment. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.085%. Furthermore, the proficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. in capital utilization is underscored by a remarkable 0.091% return on capital employed.

Stock Prices

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.54, while its low point bottomed out at $2.47. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s stock market.
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) on the HKSE in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is 0.000 in 2023.

What is the ticker symbol of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. stock?

The ticker symbol of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. stock is 1349.HK.

What is company IPO date?

IPO date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is 2002-08-13.

What is company current share price?

Current share price is 2.610 HKD.

What is stock market cap today?

The market cap of stock today is 8937971100.000.

What is PEG ratio in 2023?

The current 0.000 is 0.000 in 2023.

What is the number of employees in 2023?

In 2023 the company has 910.